Back grey_arrow_rt.gif
PSI-938 Pharmasset hepatitis drug may get faster review
Pharmasset Inc. said Wednesday that the Food and Drug Administration has awarded fast track status to its hepatitis C drug candidate PSI-938.
The FDA's decision will allow Pharmasset to submit its marketing application step by step instead of all at once. Regulators will also have the option to review the application in six months instead of the usual 10 months.
Pharmasset is studying PSI-938 as a single treatment for hepatitis C. During the third quarter it plans to start a clinical trial that will test a combination of PSI-938 and its most advanced drug candidate, PSI-977.
Shares of Pharmasset rose 97 cents to $126.18 in morning trading.
PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection - (08/24/11)
  icon paper stack View Older Articles   Back to Top